Gut Instincts:

Enhancing Immunotherapy for Brain Tumors with Bifidobacterium

Sena Nur Soyler[1], Prof. Dr. Mustafa Aziz Hatiboglu[2]

[1] Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey
[2] Bezmialem Vakif University Faculty of Medicine, Department of Neurosurgery

Exploring the Link: Gut Microbiota Shaping Brain Tumor

The discovery of the relationship between immune checkpoint inhibitors (ICI) and the gut microbiota has highlighted the gut microbiota as a potential biomarker and therapeutic target for ICI treatment. In this study, the effectiveness of anti-PD-1 (programmed cell death protein) treatment in brain tumor bearing mice treated with antibioticsand Bifidobacterium will be examined.

Our Aim: Enhancing Therapy with Microbiota?



We investigate whether modifying the microbiota enhances immunotherapy efficacy, aiming to pioneer microbiota-based brain tumor treatment strategies. This study aims to examine how chronic ABX treatment and specific bacterial colonization influence the response to immunotherpy in a preclinical model of brain tumor. Can altering the microbiota improve immunotherapy effectiveness in brain tumors?

Study Approach: Mapping the Treatment Strategy



Results

- Mice treated with antibiotics (Group2) did not show a significant increase in survival rates when treated with Anti-PD1 alone (Group4).

However, when antibiotic-treated mice were given Anti-PD1 and Bifidobacterium combination therapy (Group5), their survival rates significantly improved compared to the antibiotic treated group (Group2), with mean survival days extending from 15 ± 0.6 to 18 ± 0.5.

- This improvement was statistically significant, with a p-value of less than 0.005 (t-test).

Mice Groups	Mean Survival (days)
Group1 (tumor control)	14,4
Group2 (tumor + Abx)	15
Group3 (tumor + Abx + bifido)	16,3
Group4 (tumor + Abx + Anti-PD1)	17,2
Group5 (tumor + Abx + bifido + Anti-PD1)	18,1



Unlocking the Gut's Influence on Brain Tumor Therapy

Our findings indicate that the gut microbiota significantly influences the effectiveness of Anti-PD-1 therapy in a melanoma brain metastasis model. This study supports the concept of a functional gut–immune–brain axis, highlighting the potential of gut microbiota modulation as a novel strategy to improve outcomes in brain tumor treatments pointing towards the development of microbiota-based interventions in cancer therapy.

Looking Ahead: New Avenues in Therapy

The marked improvement in survival rates with the addition of *Bifidobacterium* suggests that targeted manipulation of the gut microbiota could pave the way for new treatment strategies. This approach may lead to more personalized and effective therapeutic interventions for patients with brain tumors, ultimately contributing to the development of microbiota-based adjuvants to immunotherapy.

References

Dees et al. (2021). *Neuro-oncology Advances*, *3*(1).

Sivan et al. (2015). *Science*, *350*(6264), 1084.

D'Alessandro et al. (2020). European Journal of Immunology, 50(5), 705.

Baruch et al. (2021) *Science*, *371*(6529), 602–609.